ALHC vs HUM: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

HUM is the larger of the two ($47.90B market cap): the incumbent the market prices for continued execution (21.42x forward earnings, beta 0.64). ALHC is the smaller challenger ($1.38B), cheaper on forward earnings (11.91x): more room to run, but more to prove. On the numbers, ALHC leads on both counts: faster expected revenue growth (25% vs 7%) and a lower forward P/E (11.91x vs 21.42x). The case for HUM rests on its own driver (Demographic tailwind in Medicare Advantage): if you believe in that, HUM fits; if you believe in what the numbers show today, ALHC does.

ALHC vs HUM: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricALHCHUMWhat it tells you
Market cap$1.38B$47.90BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E11.9121.42Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E47.2138.91Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta1.040.64Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range3% of range79% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book4.992.54How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: ALHC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how ALHC and HUM affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALHC and HUM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALHC and HUM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Alignment Healthcare (ALHC) do?

Alignment Healthcare operates Medicare Advantage health plans, mostly in California and a handful of other states, serving about 301,200 members as of the third quarter of 2026. Its model pairs a customized clinical care approach with a purpose-built technology platform (branded AVA) and local provider partnerships, aiming to deliver better health outcomes at lower cost than legacy insurers. High Star Ratings are central to the thesis because they drive bonus payments and help attract members, which is why the October 2026 release of 2027 ratings hit so hard: the share of Alignment's members in plans rated at least 4 stars fell from 98% in 2026 to 25% in 2027. Alignment has sued CMS in U.S. District Court for D.C., arguing the stars methodology was changed through technical notes rather than rulemaking, and its complaint says the drop will cost more than $200 million in 2028 payments.

Full ALHC guide

What does Humana (HUM) do?

Humana Inc. is a Louisville-based health and well-being company best known as one of the two largest Medicare Advantage insurers in the country, alongside UnitedHealth. Its Insurance segment covered roughly 7.1 million individual and group Medicare Advantage members as of early 2026, plus Medicaid, military (TRICARE), and pharmacy-benefit members. The core economics turn on the medical loss ratio, the share of premium dollars paid out as medical claims, and on CMS star ratings, which determine quality-bonus payments that fund richer plan benefits.

Full HUM guide

ALHC vs HUM: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ALHC drivers: Membership growth engine; Margin and profitability inflection.
  • HUM drivers: Demographic tailwind in Medicare Advantage; CenterWell healthcare services.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The Star Ratings collapse is now the most concrete risk: if the lawsuit fails, lower 2027 ratings cut 2028 bonus payments by more than $200 million according to the complaint, and weaker ratings can make plans less attractive during enrollment. For HUM, the medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove the earnings pressure of 2024-2025.

ALHC or HUM: which should you pick?

If the story you believe is ALHC's (Membership growth engine), ALHC is the more direct way to own it; if it is HUM's (Demographic tailwind in Medicare Advantage), HUM is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALHC and HUM guides.

ALHC vs HUM: the full fundamentals

ALHC. ALHC kept growing through 2026, yet the share price fell from a 52-week high near $25 to about $6.58 by November 20, 2026 after the 2027 Star Ratings drop and a Q3 that swung to a loss. The stock trades at under 0.3 times sales and about 12 times forward earnings, and the 12 analysts tracked by Yahoo Finance had a mean target near $10.79. The pending lawsuit against CMS and the trend in claims costs are the next markers.

HUM. At about $397, Humana trades near 39x trailing earnings, a figure inflated by depressed recent profits, and about 21x analysts' 2027 estimate of ~$18.62, which assumes earnings nearly double next year as the margin recovery and star-ratings bonuses arrive. The stock trades at only about 0.31x sales, typical of a thin-margin insurer. The 24 analysts covering it average a ~$509 target, but the November CMS audit proposal adds a policy discount that the estimates do not yet capture, and Humana's 2027 guidance, expected early in 2027, is the next major test.

Headline figures (approximate, November 2026): ALHC shows revenue (ttm) ~$4.94B, up ~37% YoY in the latest quarter, q3 2026 revenue ~$1.36B; adjusted EPS $0.05 vs $0.04 expected, net income (ttm) ~$29M (~0.6% net margin); Q3 net loss ~$8M, p/e ~47x trailing, ~12x forward; HUM shows revenue (ttm) ~$154 billion, revenue growth (q3 2026, yoy) ~26%, q3 2026 adjusted eps ~-$0.70 vs ~-$1.00 consensus, operating / net margin (ttm) ~1.8% / ~0.8%.

The bottom line: ALHC vs HUM

ALHC and HUM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ALHC and HUM exposure against your real portfolio. It is not an investment adviser.

Wondering how ALHC or HUM fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Alignment Healthcare

Ask Walnut's AI anything about ALHC and see how it fits what you own.

FAQ

What is the difference between ALHC and HUM?

+

Alignment Healthcare operates Medicare Advantage health plans, mostly in California and a handful of other states, serving about 301,200 members as of the third quarter of 2026. Humana Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ALHC or HUM the better stock?

+

Neither is universally better. HUM is the larger incumbent; ALHC is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ALHC or HUM?

+

On forward P/E (as of November 2026), ALHC trades at 11.91x and HUM at 21.42x, so ALHC is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ALHC and HUM?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ALHC vs HUM?

+

ALHC: The Star Ratings collapse is now the most concrete risk: if the lawsuit fails, lower 2027 ratings cut 2028 bonus payments by more than $200 million according to the complaint, and weaker ratings can make plans less attractive during enrollment. Medical costs have already moved against the company: Q3 2026 brought a net loss on higher catastrophic and skilled nursing costs and claims volatility after a systems migration, and margins are thin (about 0.6% net over the trailing twelve months). Membership is geographically concentrated (heavy California exposure), so state-level competition or regulatory shifts carry outsized impact. CMS policy on Star Ratings, rate benchmarks, risk coding and Medicare Advantage audits directly affects revenue and bonus payments. Sentiment has reset sharply: UBS cut its target to $9 from $22 in October 2026 and then to $8 after the Q3 report, and the 52-week low of about $6.01 sits near the current price. It also competes against far larger, better-capitalized insurers that can pressure pricing and benefits. HUM: The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove the earnings pressure of 2024-2025. Margins remain thin, with a trailing operating margin near 1.8% and net margin under 1%. Earnings are also seasonal: after a Q3 2026 adjusted loss of about $0.70 per share, consensus calls for a loss of about $7.58 in Q4, as Medicare Advantage costs build through the year. Star ratings are a second lever; the 2027 rebound helps, but ratings are recalculated every year and a slip would reduce CMS quality-bonus payments. Medicare Advantage reimbursement and broader healthcare policy are set by the government and can change rate updates, risk-adjustment rules, or audit intensity, and that risk became concrete on November 17, 2026, when CMS proposed extrapolating chart-audit error rates across whole contracts back to payment year 2018, an industry recovery CMS puts near $9 billion per payment year. A Texas court threw out the 2023 version of that rule in September 2025; the government's appeal was argued before the Fifth Circuit on October 5, 2026 and has not been decided. Because about 83% of Humana's 2025 premiums and services revenue came from federal contracts, it is more exposed than diversified peers. Finally, aggressive membership growth or repricing, such as the 2027 PPO exits, can pressure profitability or cause member attrition if benefits are trimmed too far, and after a roughly 50% rally in 2026 more of the recovery is already priced in.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ALHC or HUM; figures are approximate and dated (as of November 2026). Verify current data before investing.